| 前收市價 | 31.50 |
| 開市 | 31.44 |
| 買盤 | 31.40 x 1300 |
| 賣出價 | 31.42 x 800 |
| 今日波幅 | 31.08 - 31.81 |
| 52 週波幅 | 21.83 - 39.78 |
| 成交量 | |
| 平均成交量 | 1,003,913 |
| 市值 | 3.187B |
| Beta 值 (5 年，每月) | 1.56 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -3.94 |
| 業績公佈日 | 2023年5月02日 - 2023年5月08日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 45.88 |
- Benzinga
Evolent Health Q4 Top-Line Beats Expectation, Analyst Points To Visible Growth Outlook
Evolent Health Inc (NYSE: EVH) reported Q4 adjusted EPS of $0.10, missing the consensus of $0.16, compared to $0.08 a year ago. Revenues increased 54% Y/Y to $382.43 million, beating the consensus of $372.93 million. Total Lives on the Platform of 20.6 million as of Dec. 31, 2022, compared to 17.7 million a year ago. Total cases managed during the quarter within surgical management and advanced care planning totaled 15.7k, yielding an average per case revenue of $2.8k. Guidance: Evolent Health s
- Insider Monkey
Here’s Why Evolent Health (EVH) Declined in Q4
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. Small-cap stocks posted solid returns in the fourth quarter for the first time in 2022. The Russell 2000 Growth Index was up 4.11% trailing the Russell 2000 […]
- Benzinga
This Analyst Is Bullish On Evolent Health's Recent Deal, Calls 'Highly Strategic Acquisition'
Thursday after close, Evolent Health Inc (NYSE: EVH) agreed to acquire Magellan Specialty Health, the specialty benefit management organization owned by Centene Corporation (NYSE: CNC), for $650 million at the close plus additional contingent consideration of up to $150 million based on 2023 performance. William Blair is positive on the acquisition and believes this is consistent with management's prior commentary that Evolent would consider strategic assets that fit under the specialty care man
